Gene Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
Entrez Id: 5290
Gene Symbol: PIK3CA
PIK3CA
0.100 GeneticVariation group BEFREE On-Target Pharmacodynamic Activity of the PI3K Inhibitor Copanlisib in Paired Biopsies from Patients with Malignant Lymphoma and Advanced Solid Tumors. 31619463 2020
Entrez Id: 5290
Gene Symbol: PIK3CA
PIK3CA
0.100 Biomarker group BEFREE IL-6-induced STAT3 or STAT5 activation is a critical mechanism underlying PI3K inhibitor resistance in lymphoma, supporting the utility of IL-6 as an effective biomarker to predict therapeutic response to PI3K inhibitors. 31601188 2019
Entrez Id: 5290
Gene Symbol: PIK3CA
PIK3CA
0.100 Biomarker group BEFREE The phosphatidylinositol 3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) signaling cascade is an important therapeutic target for lymphomas. 31167506 2019
Entrez Id: 5290
Gene Symbol: PIK3CA
PIK3CA
0.100 Biomarker group BEFREE Although many PI3K inhibitors have reached different stages of clinical development, only two (idelalisib and copanlisib) have been currently approved for use in the treatment of B cell lymphoma and leukaemias. 30649751 2019
Entrez Id: 5290
Gene Symbol: PIK3CA
PIK3CA
0.100 GeneticVariation group BEFREE In addition to being frequently genetically activated in cancer, similar mutations in class I PI3Ks have now also been found in a human non-malignant overgrowth syndrome and a primary immune disorder that predisposes to lymphoma. 31110302 2019
Entrez Id: 5290
Gene Symbol: PIK3CA
PIK3CA
0.100 Biomarker group BEFREE Targeted therapy using phosphatidylinositol 3-kinase (PI3K) inhibitors is used to treat cancer such as lymphoma. 31250153 2019
Entrez Id: 5290
Gene Symbol: PIK3CA
PIK3CA
0.100 Biomarker group BEFREE We show here abundant nuclear expression of FOXO1 in Burkitt lymphoma (BL), a germinal center (GC) B-cell-derived lymphoma whose pathogenesis is linked to PI3K activation. 30333121 2018
Entrez Id: 5290
Gene Symbol: PIK3CA
PIK3CA
0.100 GeneticVariation group BEFREE Based on our recommendations, we systematically characterized all new cell lines that we generated by a standardized approach that included (1) determination of human origin, (2) exclusion of lymphoma, (3) DNA fingerprinting and histological comparisons to establish linkage to presumed tissue of origin, (4) examining thyroid differentiation by screening two to three thyroid markers, (5) examination of biological behavior (growth rate, tumorigenicity), and (6) presence of common thyroid cancer genetic changes (TP53, BRAF, PTEN, PIK3CA, RAS, TERT promoter, RET/PTC, PAX8/PPARγ, NF1, and EIF1AX). 29846633 2018
Entrez Id: 5290
Gene Symbol: PIK3CA
PIK3CA
0.100 Biomarker group BEFREE PQR309 Is a Novel Dual PI3K/mTOR Inhibitor with Preclinical Antitumor Activity in Lymphomas as a Single Agent and in Combination Therapy. 29066507 2018
Entrez Id: 5290
Gene Symbol: PIK3CA
PIK3CA
0.100 Biomarker group BEFREE As bcl-2 proteins, cyclin dependent kinases (CDK) and phosphoinositol-3- kinase (PI3K) also influence mitochondrial physiology and metabolism with clear relevance to the pathogenesis of lymphoma, we investigated the potentiating effects of metformin when combined with novel agents Venetoclax (bcl-2 inhibitor), BAY-1143572 (CDK9 inhibitor) and Idelalisib (p110δ- PI3K inhibitor). 29765528 2018
Entrez Id: 5290
Gene Symbol: PIK3CA
PIK3CA
0.100 Biomarker group BEFREE BET Inhibition-Induced GSK3β Feedback Enhances Lymphoma Vulnerability to PI3K Inhibitors. 30134175 2018
Entrez Id: 5290
Gene Symbol: PIK3CA
PIK3CA
0.100 Biomarker group BEFREE Collectively, these data provide a mechanistic rationale for evaluating CUDC-907 for the treatment of patients with Myc and PI3K-dependent lymphomas. 28147336 2017
Entrez Id: 5290
Gene Symbol: PIK3CA
PIK3CA
0.100 Biomarker group BEFREE Idelalisib is a PI3Kδ inhibitor that has been approved for the treatment of lymphoma and chronic lymphocytic leukemia in the relapsed/refractory setting, and several other PI3K inhibitors are being developed targeting other isoforms of the PI3K enzyme, which results in distinct toxicities and variable efficacy in the clinical setting. 28112970 2017
Entrez Id: 5290
Gene Symbol: PIK3CA
PIK3CA
0.100 Biomarker group BEFREE Targeting the PI3K/mTOR pathway in several types of lymphoma has shown preclinical and clinical efficacy providing the rationale to test this strategy in the treatment of relapsed/refractory indolent lymphomas. 28211162 2017
Entrez Id: 5290
Gene Symbol: PIK3CA
PIK3CA
0.100 Biomarker group BEFREE We evaluate PI3K inhibitors that have entered trials for the treatment of lymphoma, focusing on agents with selectivity for PI3Kα and PI3Kδ. 28945111 2017
Entrez Id: 5290
Gene Symbol: PIK3CA
PIK3CA
0.100 Biomarker group BEFREE Perhaps because of the central role played by PI3K in BCR signaling, B cell leukemia and lymphomas are the first diseases for which a PI3K inhibitor has been approved for clinical use. 26350103 2016
Entrez Id: 5290
Gene Symbol: PIK3CA
PIK3CA
0.100 AlteredExpression group BEFREE We show that lymphomas developing in a Pde4b-null background display significantly lower microvessel density (MVD) in association with lower VEGF levels and PI3K/AKT activity. 26503641 2016
Entrez Id: 5290
Gene Symbol: PIK3CA
PIK3CA
0.100 AlteredExpression group BEFREE Here, we demonstrate that coordinated targeting of rDNA transcription and PI3K-AKT-mTORC1-dependent ribosome biogenesis and protein synthesis provides a remarkable improvement in survival in MYC-driven B lymphoma. 26490423 2016
Entrez Id: 5290
Gene Symbol: PIK3CA
PIK3CA
0.100 Biomarker group BEFREE Constitutive activation of the phosphatidyl-inositol-3-kinase (PI3K)/Akt/mammalian target of rapamycin (mTOR) signaling pathway is often detected in this lymphoma. 23721513 2014
Entrez Id: 5290
Gene Symbol: PIK3CA
PIK3CA
0.100 Biomarker group BEFREE As drug resistance remains a major challenge and CDK4 and PI3K are dysregulated at a high frequency in human cancers, targeting CDK4 in genome-based combination therapy represents a novel approach to lymphoma and cancer therapy. 25082755 2014
Entrez Id: 5290
Gene Symbol: PIK3CA
PIK3CA
0.100 Biomarker group BEFREE Collectively, our results indicate that PTEN loss defines a PI3K/AKT-dependent GCB DLBCL subtype that is addicted to PI3K and MYC signaling and suggest that pharmacologic inhibition of PI3K might represent a promising therapeutic approach in these lymphomas. 23840064 2013
Entrez Id: 5290
Gene Symbol: PIK3CA
PIK3CA
0.100 Biomarker group BEFREE The role of PI3K inhibition in the treatment of lymphomas has not been fully delineated. 23300274 2013
Entrez Id: 5290
Gene Symbol: PIK3CA
PIK3CA
0.100 Biomarker group BEFREE The phosphatidylinositol-3-kinase (PI3K) / protein kinase B (AKT) signal transduction pathway is commonly misregulated in lymphoma and associated with tumorigenesis and enhanced resistance to radiotherapy. 23603894 2013
Entrez Id: 5290
Gene Symbol: PIK3CA
PIK3CA
0.100 AlteredExpression group BEFREE Accordingly, miR-17~92-driven lymphoma cells exhibited constitutive activation of the PI3K and NFκB pathways and chemical inhibition of either pathway reduced tumour size and prolonged the survival of lymphoma-bearing mice. 23921550 2013
Entrez Id: 5290
Gene Symbol: PIK3CA
PIK3CA
0.100 Biomarker group BEFREE Finally, HRS cells display deregulated expression of several genes potentially highly relevant to lymphoma pathogenesis, including silencing of the apoptosis-inducer BIK and of INPP5D, an inhibitor of the PI3K-driven oncogenic pathway. 22955914 2012